Sign in →

Test ID HIBS Haemophilus influenzae Type B Antibody, IgG, Serum

Reporting Name

Haemophilus influenzae B Ab, IgG, S

Useful For

Assessing a patient's immunological (IgG) response to Haemophilus influenzae type B (HIB) vaccine

 

Assessing immunity against HIB

 

Aiding in the evaluation of immunodeficiency when the patient is tested pre- and postvaccination

Specimen Type

Serum


Specimen Required


Container/Tube: 

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 0.5 mL


Specimen Minimum Volume

0.2 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  7 days

Reference Values

≥0.15 mg/L

Reference values apply to all ages.

Day(s) and Time(s) Performed

Monday, Wednesday, Friday; 8 a.m.

Test Classification

This test has been cleared, approved or is exempt by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86684

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HIBS Haemophilus influenzae B Ab, IgG, S 11257-3

 

Result ID Test Result Name Result LOINC Value
83261 Haemophilus influenzae B Ab, IgG, S 11257-3

Clinical Information

Haemophilus influenzae type B (HIB) is an encapsulated gram-negative cocco-bacillary bacterium that can cause devastating disease in young children including meningitis, bacteremia, cellulitis, epiglottitis, pneumonia, and septic arthritis.

 

One of the great advances in modern medicine has been the development of an effective vaccine against HIB. A patient's immunological response to HIB vaccine can be determined by measuring anti-HIB IgG antibody using this enzyme immunoassay (EIA) technique.

Interpretation

An anti-Haemophilus influenzae type B (HIB) IgG antibody concentration of 0.15 mg/L is generally accepted as the minimum level for protection at a given time; however, it does not confer long-term protection. A study from Finland suggested that the optimum protective level is 1.0 mg/L postimmunization.(1) Furthermore, studies have shown that the response to HIB vaccine is age-related.

Clinical Reference

1. Peltola H, Kayhty H, Virtanen M, et al: Prevention of Haemophilus influenzae type B bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med. 1984;310(24):1561-1566

2. Berger M: Immunoglobulin G subclass determination in diagnosis and management of antibody deficiency syndromes. J Pediatr. 1987;110(2):325-328

3. Murphy TF: Haemophilus species, including H influenzae and H ducreyi (Chancroid). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:2743-2752

Analytic Time

Same day/1 day

Method Name

Enzyme Immunoassay (EIA)